Understanding the Tailwind Behind Stevanato Shares.

Stevanato stock is trading -30.45% below its average target price of $29.08 after marking a 4.3% during today's morning session. Analysts are giving the Mid-Cap Medical Instruments & Supplies company an average rating of buy and target prices ranging from $22.21 to $37.99 per share.

The stock has an average amount of shares sold short at 5.7%, and a short ratio of 7.94. Since 2.13% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 112.8% of Stevanato's shares being owned by this investor type.

Institutions Invested in Stevanato

Date Reported Holder Percentage Shares Value
2024-03-31 Conestoga Capital Advisors, LLC 2% 6,778,893 $137,103,113
2024-03-31 Neuberger Berman Group, LLC 1% 4,396,287 $88,914,906
2024-03-31 Copeland Capital Management, LLC 1% 2,402,115 $48,582,776
2024-03-31 Lazard Asset Management LLC 1% 2,267,013 $45,850,338
2024-03-31 Wellington Management Group, LLP 1% 2,210,883 $44,715,109
2024-03-31 Sands Capital Management, LLC 1% 1,860,141 $37,621,352
2024-03-31 Jackson Square Partners, Llc 1% 1,824,240 $36,895,254
2024-03-31 ClearBridge Investments, LLC 1% 1,729,397 $34,977,054
2024-03-31 Times Square Capital Management, LLC 1% 1,626,063 $32,887,124
2024-03-31 William Blair Investment Management, LLC 0% 1,432,868 $28,979,755

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Stevanato.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.